Brent T. Lucas
Known title: Chief Executive OfficerCIK: 0001994382
Brent T. Lucas's purchase track record
Brent T. Lucas has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/12/2026 | COCH | $25K | +26.7% | +43.1% | +14.1% |
| 11/21/2023 | COCH | $12K | +28.9% | +214.4% | +17.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| COCH | ▲ Buy | Grant | 32,856 | $20K | 5/29/2026 | View on chart |
| COCH | ▲ Buy | Open Market | 62,500 | $25K | 2/12/2026 | View on chart |
| COCH | ▲ Buy | Grant | 18,105 | $13K | 11/28/2025 | View on chart |
| COCH | ▲ Buy | Grant | 7,742 | $10K | 5/30/2025 | View on chart |
| COCH | ▲ Buy | Grant | 5,165 | $10K | 11/30/2024 | View on chart |
| COCH | ▼ Sell | Other | 74,784 | $0 | 6/24/2024 | View on chart |
| COCH | ▼ Sell | Other | 10,176 | $0 | 6/24/2024 | View on chart |
| COCH | ▲ Buy | Open Market | 10,000 | $10K | 11/21/2023 | View on chart |
| COCH | ▲ Buy | Open Market | 2,380 | $2K | 11/21/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Envoy Medical Adds Two New Patents to Global Portfolio
Envoy Medical announced it has been granted two additional global patents, further expanding its intellectual property portfolio. This development strengthens the company's protection for its medical technologies. The stock is currently trading near its 52-week low, with an average analyst target of $2.00.
Envoy Medical Adds Two New Patents to Global Portfolio. Envoy Medical announced it has been granted two additional global patents, further expanding its intellectual property portfolio. This development strengthens the company's protection for its medical technologies. The stock is currently trading near its 52-week low, with an average analyst target of $2.00.